162 related articles for article (PubMed ID: 20524257)
21. Clinical trials referral resource. Clinical trials of MGI-114.
Murgo A; Cannon DJ; Blatner G; Cheson BD
Oncology (Williston Park); 1999 Feb; 13(2):233, 237-8. PubMed ID: 10079472
[No Abstract] [Full Text] [Related]
22. [Drug development in paediatric oncology].
Benninger-Döring G; Boos J
Klin Padiatr; 2006; 218(3):152-6. PubMed ID: 16688671
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin in cancer-related anemia.
Fenner MH; Ganser A
Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
[TBL] [Abstract][Full Text] [Related]
24. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
Tuma RS
J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
[No Abstract] [Full Text] [Related]
25. Oncology drug discovery: planning a turnaround.
Toniatti C; Jones P; Graham H; Pagliara B; Draetta G
Cancer Discov; 2014 Apr; 4(4):397-404. PubMed ID: 24706659
[TBL] [Abstract][Full Text] [Related]
26. [The introduction of new drugs from the basic research to clinical application--issues in the drug development].
Watanabe T; Saijo N
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():289-91. PubMed ID: 7986105
[No Abstract] [Full Text] [Related]
27. Clinical trials referral resource. Current clinical trials of bortezomib.
Wright JJ; Zerivitz K; Schoenfeldt M
Oncology (Williston Park); 2003 May; 17(5):677-80, 683-6, 691-2. PubMed ID: 12800794
[No Abstract] [Full Text] [Related]
28. Drug discovery in the p53 field.
Lain S
Semin Cancer Biol; 2010 Feb; 20(1):1-2. PubMed ID: 20359536
[No Abstract] [Full Text] [Related]
29. Clinical trials referral resource. Current clinical trials of agents targeting epidermal growth factor receptor.
Dancey JE; Schoenfeldt M
Oncology (Williston Park); 2003 Jun; 17(6):819, 826-30, 833-4 passim. PubMed ID: 12846126
[No Abstract] [Full Text] [Related]
30. Rethinking clinical trials for cytostatic drugs.
Millar AW; Lynch KP
Nat Rev Cancer; 2003 Jul; 3(7):540-5. PubMed ID: 12835674
[TBL] [Abstract][Full Text] [Related]
31. [Recent proposals for early stage clinical trials of cancer].
Ohashi Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():292-4. PubMed ID: 7986106
[TBL] [Abstract][Full Text] [Related]
32. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
Lebwohl D; Kay A; Berg W; Baladi JF; Zheng J
Cancer J; 2009; 15(5):386-94. PubMed ID: 19826358
[TBL] [Abstract][Full Text] [Related]
33. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
34. Progression-free survival remains debatable endpoint in cancer trials.
Tuma R
J Natl Cancer Inst; 2009 Nov; 101(21):1439-41. PubMed ID: 19828873
[No Abstract] [Full Text] [Related]
35. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
Brumlik MJ; Daniel BJ; Waehler R; Curiel DT; Giles FJ; Curiel TJ
Expert Opin Drug Deliv; 2008 Jan; 5(1):87-103. PubMed ID: 18095930
[TBL] [Abstract][Full Text] [Related]
36. Another STEPP in the right direction.
Bonetti M; Cole BF; Gelber RD
J Clin Oncol; 2008 Aug; 26(22):3813-4; author reply 3814-5. PubMed ID: 18669475
[No Abstract] [Full Text] [Related]
37. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
38. Anticancer drug discovery in the future: an evolutionary perspective.
Ma X; Wang Z
Drug Discov Today; 2009 Dec; 14(23-24):1136-42. PubMed ID: 19800414
[TBL] [Abstract][Full Text] [Related]
39. Discontinued drugs in 2008: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
[TBL] [Abstract][Full Text] [Related]
40. [Clinical trials of combinations of molecular targeting drugs for head and neck cancer].
Fujii M
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1122-5. PubMed ID: 18686361
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
